Know Cancer

forgot password

A Phase IB/II Multi-Center Clinical Study of PHY906 as a Modulator of CPT-11 Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 1/Phase 2
18 Years
Open (Enrolling)
Colorectal Neoplasms

Thank you

Trial Information

A Phase IB/II Multi-Center Clinical Study of PHY906 as a Modulator of CPT-11 Chemotherapy in Patients With Metastatic Colorectal Cancer

Inclusion Criteria:

- Patients must have histologically confirmed malignancy that is metastatic or
unresectable and for which standard curative or palliative measures do not exist or
are no longer effective (Phase I Part).

- Patients with histologically confirmed metastatic colorectal cancer, who failed with
prior two different chemotherapy regimens (Phase II Part).

- At least one evaluable lesion. Lesions must be evaluated by computerized tomography
(CT), magnetic resonance imaging (MRI), or PET scan (Phase I Part).

- At least one measurable lesion by CT or MRI of ≥ 20 mm (if conventional CT scan) or ≥
10 mm (if spiral CT scan) (Phase II part)

- Karnofsky Performance Status ≥ 60%

- Must be ≥18 years of age.

- Expected survival of at least 3 months for phase I part, and at least 6 months for
phase II part.

- Women of child-bearing potential (i.e., women who are pre-menopausal or not
surgically sterile) must use acceptable contraceptive methods (abstinence,
intrauterine device [IUD], oral contraceptive or double barrier device), and must
have a negative serum or urine pregnancy test within 1 week prior to beginning
treatment on this trial. Nursing patients are excluded. Sexually active men must also
use acceptable contraceptive methods. Pregnant and nursing patients are excluded
because the effects of the combination of PHY906 and CPT-11 on a fetus or nursing
child are unknown.

- Must be able and willing to give written informed consent.

- Patients must have the following clinical laboratory values:

ANC count ≥ 1,500/ mm3. Platelets ≥ 100,000/ mm3. Serum creatinine ≤ 2x upper limit of
normal. Total bilirubin < 1.5x upper limit of normal. Serum calcium < 12.0 mg/dl. Alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x the upper limit of normal
(≤ 5.0 x ULN is acceptable if liver has tumor involvement) Prothrombin Time (PT),
activated partial thromboplastin time (aPTT) and INR ≤ 1.5 x ULN or in the therapeutic
range if on anticoagulation Hemoglobin ≥ 9 gm/dl (may be corrected by transfusion).

Exclusion Criteria:

- Symptomatic brain metastasis.

- Serious concomitant systemic disorders (e.g., active infection) that, in the opinion
of the investigator, would compromise the safety of the patient or compromise the
patient's ability to complete the study.

- Unwilling or unable to follow protocol requirements or to give informed consent.

- No treatment with cytotoxic or biologic agents within the 4 weeks prior to beginning
treatment on this study (6 weeks for mitomycin or nitrosoureas). At least 4 weeks
must have elapsed from any prior surgery, radiation, hormonal or other drug therapy
for their cancer.

- Known HIV positivity, as safety in this patient population has not been assessed.

- Presence of metastatic disease that, in the opinion of investigators, would require
palliative treatment within 4 weeks of enrollment.

- Altered mental status precluding understanding of the informed consent process and/or
completion of the necessary studies.

- Pregnant or breast-feeding women.

- Men and women of childbearing age and potential, who are not willing to use effective

- Major surgery within the last 4 weeks.

- Patients taking concurrent medications of any kind which are strong inducers or
inhibitors of CYP3A4. Patients receiving any of the following will be excluded:
ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone,
nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, phenytoin,
carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine maximum tolerated dose of PHY906 when combined with a standard dose of CPT-11 and to determine response rate in patients with metastatic colorectal cancer

Outcome Time Frame:

Maximum tolerated dose will be available at end of Phase I while response rate will be available upon completion of study.

Safety Issue:


Principal Investigator

Wasif Saif, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Yale University Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

December 2008

Completion Date:

December 2010

Related Keywords:

  • Colorectal Neoplasms
  • Neoplasms
  • Colorectal Neoplasms



Yale University Comprehensive Cancer Center New Haven, Connecticut  06520
VACT Cancer Center West Haven, Connecticut  06516